| March 19, 2022  Editor's Note: The message below from one of our partners is one we believe you should take a close look at. Dear Reader, Cytarbine. That's the name of the most popular drug doctors prescribed last year to fight leukemia. Problem is, Cytarbine is a "chemical drug" that was patented almost 60 years ago. Chemical drugs are like nuclear weapons. Drop them inside your body and everything gets destroyed. It's why people say, "the chemo will get you before the cancer does." It gets even worse... 75% of all cancer drugs sold by Big Pharma are old chemical drugs like Cytarbine. Well guess what? On September 10, 2018, a tiny Cambridge biotech firm won a patent on a new kind of treatment that can "Cut & Paste" any disease from your body. It's like this tiny biotech invented the iPhone while Big Pharma is still selling flip phones. And our research proves that anyone who gets in today could to see a 46,751% return (or more)! The Big Pharma companies that have the most to lose from this new treatment are Bristol Meyers, Pfizer, Sanofi, Novartis and Teva. Sanofi has their own new drug on the market. Pfizer last month bought Array Biopharma, which we recommended. That leaves Novartis, Teva and Bristol Meyers. We think Bristol Meyers is the most likely buyer because their new leukemia drug recently flunked out of FDA trials. A deal could happen any day. A takeover of the company could hand investors gains of up to 31,250% in the next 90 days... But we would be ok if there wasn't a deal. That's because Investor's Business Daily estimates this is a $75 billion market. Yet right now, its stock price is just a tiny fraction of that size. CLICK HERE to see how you can profit from this rare opportunity>>>
Simmy Adelman, Editor
Trading involves risk. The information provided is NOT trading advice. Neither the Editors, the Publisher, nor any of their respective affiliates make any guarantee or other promise as to any results that may be obtained from the newsletter. Past performance is no guarantee of future performance. This recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability for any purchase or order made from any company or entity mentioned or recommended in this email. |
Post a Comment
0Comments